EMBER-3 data show switching to the combination at progression nearly doubled PFS versus imlunestrant alone in ESR1-mutated advanced breast cancer.
Commentary|Podcasts|March 20, 2023
Pharmacy Focus: Oncology Edition - Breast Cancer Treatments Are Rapidly Expanding
This month, we spoke with Danielle Roman, PharmD, an oncology clinical pharmacy specialist with Allegheny Health Network.
Advertisement
This month, we spoke with Danielle Roman, PharmD, an oncology clinical pharmacy specialist with Allegheny Health Network. Roman discussed the rapidly growing breast cancer treatment space, as well as pharmacists' roles in the complex treatment regimens.
Interested in learning more? Check out this related content:
Advertisement
Related to this article
The all-oral combination is supported by phase 3 LITESPARK-011 data showing improved progression-free survival compared with cabozantinib.
The FDA approved lirafugratinib for adults with previously treated, advanced cholangiocarcinoma harboring an FGFR2 fusion or other rearrangement after the REFOCUS trial showed a 46% ORR.
Long-term CASSIOPEIA Registry results show that daratumumab maintenance supports sustained minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma.
Infection prevention during bispecific antibody treatment requires pharmacists to coordinate baseline screening, antimicrobial prophylaxis, immunoglobulin monitoring, vaccination, and rapid evaluation of suspected infections.
For as long as practicing oncology pharmacists have been in the field, multiple myeloma has carried a standard caveat: treatable, not curable. Now that is changing.
Linvoseltamab drives deep, MRD-negative responses in high-risk smoldering multiple myeloma, raising earlier-treatment and payer coverage questions.
A phase 1/2 analysis found rapid, deep responses with mezigdomide plus elranatamab in patients with relapsed or refractory multiple myeloma, but the small cohort and limited follow-up require cautious interpretation.
Advertisement
Advertisement
Trending on Pharmacy Times
1
After 180 Years, Multiple Myeloma Gets a Definition of Cure
2
Severe Asthma's Effects May Extend Beyond the Lungs, Brain Imaging Study Suggests
3
Alcohol and GLP-1 Therapy: Key Counseling Points for Pharmacists
4
Psilocybin-Assisted Therapy for AUD: Emerging Evidence, Clinical and Cost Implications, and Treatment Gaps
5